GLBE Stock

Business

Beyond the Headlines: Three ASX Penny Stocks Drawing Investor Scrutiny Amid Market Volatility

While broader market sentiment remains cautious, a closer look reveals potential in select small-cap opportunities. We examine three ASX-listed penny stocks—Argenica Therapeutics, SenSen Networks, and Vita Life Sciences—that are navigating unique paths in biotech, AI, and healthcare, offering distinct risk-reward profiles for discerning investors.

Feb 5, 2026

Business

Amcor's Stock Surge Sparks Valuation Debate: Is the Packaging Giant Overvalued or Poised for Growth?

Amcor's shares have posted double-digit gains over recent weeks, sharply contrasting with its muted annual performance. This surge has ignited a fierce debate among investors over whether the stock is catching up to its true value or if the rally has already priced in overly optimistic expectations.

Feb 5, 2026

Business

GE HealthCare Stock Slump: A Buying Opportunity or a Value Trap?

GE HealthCare Technologies' shares have faced recent pressure, lagging behind broader market and industry peers. A deep dive into valuation metrics, including discounted cash flow and P/E analysis, suggests the stock may be significantly undervalued. We examine the numbers and the narratives shaping investor sentiment.

Feb 5, 2026

Business

Tesla's Soaring Valuation: Is the Stock Price Detached from EV Reality?

Tesla's stock, a bellwether for the electric vehicle revolution, faces intense scrutiny as valuation metrics signal a significant premium. While long-term returns remain impressive, recent volatility and fundamental analysis raise questions about whether the current price fully accounts for mounting competition and execution risks.

Feb 5, 2026

Business

STERIS Stock: A 20% Surge Leaves Investors Wondering If the Rally Has Run Its Course

STERIS plc's shares have climbed over 20% in the past year, prompting a critical valuation debate. While a discounted cash flow model suggests the stock is fairly priced, its elevated P/E ratio compared to industry peers raises questions about its current premium. We examine the metrics and investor narratives shaping the outlook for this healthcare infrastructure leader.

Feb 4, 2026

Business

AI Anxiety Triggers Tech Rout: Software and Chip Stocks Tumble as Investors Question Boom's Sustainability

A wave of selling swept through global technology stocks this week, erasing hundreds of billions in market value, as conflicting fears over artificial intelligence's disruptive potential and its near-term demand rattled Wall Street.

Feb 4, 2026

Business

Beyond the Downturn: Three ASX Penny Stocks Defying Market Gloom

Amidst a cautious market environment shaped by RBA rate hikes and global tech volatility, a closer look reveals resilient opportunities. We examine three ASX-listed penny stocks—from biotech to mining—that are navigating the headwinds with distinct strategies and potential.

Feb 4, 2026

Business

Bitcoin Breaches $73K Support, Mining Stocks Plunge as Crypto Correction Intensifies

Bitcoin fell below $73,000 on Feb. 4, 2026, reaching its lowest level since April 2025 and triggering a double-digit selloff in major mining stocks. The decline extends a four-month retreat from all-time highs, pressured by large holder sales and waning mining profitability.

Feb 4, 2026

Business

AI's Hidden Winners: Memory Chip Stocks Soar Over 1,000% as Data Center Boom Fuels Critical Shortage

Beyond the spotlight on Nvidia and ChatGPT, the AI infrastructure rush is creating a historic surge for memory and storage chipmakers, with stock gains eclipsing 1,000% as supply struggles to meet explosive data center demand.

Feb 4, 2026

Business

Figma's Stock Plunge: AI Anxiety and Analyst Downgrades Rattle Design Software Sector

Figma shares have tumbled sharply, caught in a broader sell-off of design software stocks fueled by analyst pessimism and mounting concerns over AI's disruptive potential. The sell-off raises questions about whether the market is overreacting or correctly pricing in new competitive risks.

Feb 4, 2026

Business

Beyond the Penny Label: Three TSX-Listed Stocks Drawing Investor Scrutiny Amid Strong Earnings Season

As the TSX rides a wave of positive earnings momentum, investors are sifting through smaller-cap names for growth potential. We examine three companies—spanning crypto, energy, and digital assets—that are catching the eye of analysts, despite the inherent risks of the 'penny stock' category.

Feb 4, 2026

Business

Amazon's Q4 Earnings Preview: Can Retail, Cloud, and Advertising Momentum Drive a Stock Rebound?

As Amazon prepares to report its fourth-quarter results, strong performance across its core businesses is expected. Yet, despite solid fundamentals, the stock has languished, leaving investors to weigh near-term AI costs against long-term growth potential.

Feb 4, 2026

Business

Cramer Cools on Moderna's Rally, Prefers Other Pharma Bets Despite Stock Recovery

CNBC's Jim Cramer acknowledged Moderna's strong January performance but expressed caution, noting the company faces years of unprofitability and highlighting other pharmaceutical and biotech stocks he finds more attractive for investment.

Feb 4, 2026

Business

The Peril of Chasing Lows: Why 'Bottom Fishing' in Beaten-Down Stocks Could Sink Your Portfolio

As major software stocks hit 52-week lows, a chorus of Wall Street analysts warns investors against the temptation to 'buy the dip,' citing momentum studies that show falling knives often keep falling.

Feb 4, 2026

Business

Argan (AGX) Stock Soars 194% in a Year: Is the Rally Running on Fumes?

Argan's shares have skyrocketed, closing at $381.73 after a 194% annual surge. However, a deep dive into valuation metrics suggests the stock may be significantly overvalued, raising questions about its current risk-reward profile for investors.

Feb 4, 2026

Business

TriCo Bancshares Stock Surge Prompts Valuation Debate: Is the Rally Justified?

Shares of regional lender TriCo Bancshares (TCBK) have posted strong gains over the past quarter, outpacing broader bank indices. This momentum has ignited a fresh debate among analysts and investors: Is the stock still a value play, or has the market run ahead of itself?

Feb 4, 2026

Business

Amphenol's Soaring Stock: Is There Any Value Left After the Rally?

Amphenol's shares have delivered stellar multi-year returns, leaving investors to question if the connectivity giant is still a buy. A deep dive into valuation metrics reveals a stock trading near fair value, but with significant optimism already priced in.

Feb 4, 2026

Business

Modine Manufacturing's Meteoric Rise: Is the Stock Still a Buy After Doubling in a Year?

Shares of thermal management specialist Modine Manufacturing have more than doubled over the past year, fueled by data center cooling demand. As the stock trades near record highs, investors are weighing whether its premium valuation is justified by future growth prospects.

Feb 4, 2026

Business

CBRE Group's Soaring Stock: Is the Commercial Real Estate Giant Priced for Perfection?

After years of impressive gains, CBRE Group's stock faces scrutiny. A deep dive into valuation metrics suggests the market may be pricing in excessive optimism, raising questions about future returns for investors.

Feb 4, 2026

Business

AppLovin's Stock Slide: A Buying Opportunity or a Sign of Slowing Momentum?

AppLovin's shares have faced significant pressure recently, declining roughly 25% over the past month and year-to-date. This slump contrasts sharply with its stellar long-term returns and blockbuster Q3 earnings, leaving investors to debate whether the stock is now undervalued or if growth concerns are justified.

Feb 4, 2026